International union of pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors

Francoise Bachelerie, Adit Ben-Baruch, Amanda M. Burkhardt, Christophe Combadiere, Joshua M. Farber, Gerard J. Graham, Richard Horuk, Alexander Hovard Sparre-Ulrich, Massimo Locati, Andrew D. Luster, Alberto Mantovani, Kouji Matsushima, Philip M. Murphy, Robert Nibbs, Hisayuki Nomiyama, Christine A. Power, Amanda E I Proudfoot, Mette M. Rosenkilde, Antal Rot, Silvano SozzaniMarcus Thelen, Osamu Yoshie, Albert Zlotnik

Research output: Contribution to journalArticle

Abstract

Sixteen years ago, the Nomenclature Committee of the International Union of Pharmacology approved a system for naming human seventransmembrane (7TM) G protein-coupled chemokine receptors, the large family of leukocyte chemoattractant receptors that regulates immune system development and function, in large part by mediating leukocyte trafficking. This was announced in Pharmacological Reviews in a major overview of the first decade of research in this field [Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) Pharmacol Rev 52:145-176]. Since then, several new receptors have been discovered, and major advances have been made for the others in many areas, including structural biology, signal transduction mechanisms, biology, and pharmacology. New and diverse roles have been identified in infection, immunity, inflammation, development, cancer, and other areas. The first two drugs acting at chemokine receptors have been approved by the U.S. Food and Drug Administration (FDA), maraviroc targeting CCR5 in human immunodeficiency virus (HIV)/AIDS, and plerixafor targeting CXCR4 for stem cell mobilization for transplantation in cancer, and other candidates are now undergoing pivotal clinical trials for diverse disease indications. In addition, a subfamily of atypical chemokine receptors has emerged that may signal through arrestins instead of G proteins to act as chemokine scavengers, and many microbial and invertebrate G protein-coupled chemokine receptors and soluble chemokine-binding proteins have been described. Here, we review this extended family of chemokine receptors and chemokine-binding proteins at the basic, translational, and clinical levels, including an update on drug development. We also introduce a new nomenclature for atypical chemokine receptors with the stem ACKR (atypical chemokine receptor) approved by the Nomenclature Committee of the International Union of Pharmacology and the Human Genome Nomenclature Committee.

Original languageEnglish
Pages (from-to)1-79
Number of pages79
JournalPharmacological Reviews
Volume66
Issue number1
DOIs
Publication statusPublished - Jan 2014

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., Mantovani, A., Matsushima, K., Murphy, P. M., Nibbs, R., Nomiyama, H., Power, C. A., Proudfoot, A. E. I., Rosenkilde, M. M., Rot, A., ... Zlotnik, A. (2014). International union of pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacological Reviews, 66(1), 1-79. https://doi.org/10.1124/pr.113.007724